a2z-Unified-Triage

Evidence summary

Study type: Stand-Alone Performance. Cases: 675. Sites: 12. Reference standard: Interpretation by Reviewing Clinician. Reported sensitivity: Acute Cholecystitis: 96.1% [89.2-98.7%], Acute Pancreatitis: 98.0% [92.9-99.4%], Unruptured AAA: 100.0% [95.2-100.0%, Acute Diverticulitis: 98.7% [92.9-99.8%], Free Air: 89.3% [82.2-93.8%], Hydronephrosis: 89.7% [82.1-94.3%], Small Bowel Obstruction: 94.9% [88.7-97.8%]. Reported specificity: Acute Cholecystitis: 89.3% [86.6-91.5%], Acute Pancreatitis: 87.8% [84.9-90.3%], Unruptured AAA: 86.3% [83.3-88.8%], Acute Diverticulitis: 89.3% [86.6-91.5%], Free Air: 88.6% [85.7-91.0%], Hydronephrosis: 92.9% [90.5-94.7%], Small Bowel Obstruction: 91.7% [89.1-93.7%]

Public source Exact FDA submission Checked 2026-09-01

Structured study metadata from the exact-submission ACR model card; this is not an independent evidence synthesis.

• Source

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Postmarket safety review

Not established in reviewed sources

Reviewed sources checked Exact FDA submission Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

• Verify security and privacy controls: FDA authorization does not establish the current commercial security posture. Request data-flow diagrams, hosting and retention details, access controls, audit logging, attestations, and incident-response documentation.
• Verify training: Training, onboarding, competency, and support commitments are commercial implementation details that require current vendor documentation.
• Verify pricing and total cost: FDA submission materials do not establish current commercial pricing. Request the pricing unit, term, minimum commitment, implementation fees, and included support from the vendor.
• Verify reimbursement and coding relevance: Determine whether any product-specific CPT/HCPCS pathway exists and separate it from billing for the underlying imaging service.
• Verify local validation and lifecycle monitoring: Local acceptance testing, production monitoring, drift review, update control, and incident escalation require a current vendor and site-specific governance plan.
• Verify recalls and postmarket safety signals: No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Exact-submission ACR model-card fields were normalized under the current provenance rules; vendor and independent-study confirmation remain distinct. Automated exact-name discovery found 0 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, acr ai central product, pubmed, clinical trials, openfda device recall

• K252366 FDA decision source U.S. Food and Drug Administration · 2026-08-31
• Artificial Intelligence-Enabled Medical Devices U.S. Food and Drug Administration · 2026-08-31
• a2z-Unified-Triage model card (K252366) American College of Radiology · 2026-09-01
• PubMed biomedical literature index U.S. National Library of Medicine · 2026-09-01
• ClinicalTrials.gov study registry U.S. National Library of Medicine · 2026-09-01
• openFDA Device Recall API U.S. Food and Drug Administration · 2026-09-02